North America - United States • Antitrust
O'Melveny & Myers LLP
We only have limited information for this firm. Consider the following firms which have provided more information:
O'Melveny & Myers LLP has an active antitrust litigation practice with a strong track record securing victories for clients in bet-the-company cases, conspiracy cases, and reverse payment litigations. Ian Simmons and Ben Bradshaw jointly lead the antitrust team; Simmons has extensive experience as lead counsel in multi-district antitrust litigations across a range of sectors and also handles cartel matters and antitrust-related IP litigation. Bradshaw is a key contact for clients in the aviation, proteins, and consumer electronics sectors and routinely takes point on competitor-on-competitor litigation in the pharma space. Both are based in Washington DC. Also in DC, Sergei Zaslavsky handles bench and jury trials as well as Sherman Act class actions for clients from the tech, banking, and healthcare industries. Andrew Frackman, in New York, has a broad practice spanning anti-competitive business practices, merger litigation, and general antitrust litigation in the financial services and airline industries. Peter Herrick joined the team from Axinn Veltrop & Harkrider in February 2023 and takes point on merger litigation; Herrick is also based in New York. Katrina Robson left the firm in April 2023.
Legal 500 Editorial commentary
Key clients
- American Airlines
- BH Management Services LLC
Abbreviated data is displayed for this firm.
Work highlights
- Successfully represented US Airways (now part of American Airlines Group) in long-running litigation against Sabre after the Second Circuit reversed a Section 1 jury verdict on grounds the jury instruction was inconsistent with the subsequent 2018 Supreme Court decision in Ohio v. American Express.
- Obtained a victory for C. R. Bard in a Northern District of New York jury trial, defending a Sherman Act tying claim brought by AngioDynamics, who claimed C. R. Bard violated the federal antitrust laws by tying the sale of its tip location system to its line of peripherally inserted central catheters, which allegedly prevented competition in the marketplace and limited patient access to alternate technologies.
Abbreviated data is displayed for this firm.